Morgan Stanley Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $110

Morgan Stanley analyst Michael Ulz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $130 to $110.